1. Home
  2. BGSF vs CYPH Comparison

BGSF vs CYPH Comparison

Compare BGSF & CYPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BGSF Inc.

BGSF

BGSF Inc.

N/A

Current Price

$5.63

Market Cap

64.0M

ML Signal

N/A

CYPH

Cypherpunk Technologies Inc.

HOLD

Current Price

$0.75

Market Cap

73.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BGSF
CYPH
Founded
2007
2011
Country
United States
United States
Employees
N/A
6
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
64.0M
73.4M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
BGSF
CYPH
Price
$5.63
$0.75
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
6.9K
2.5M
Earning Date
05-06-2026
05-13-2026
Dividend Yield
36.04%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$93,310,000.00
N/A
Revenue This Year
$4.67
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.26
$0.49
52 Week High
$8.20
$3.70

Technical Indicators

Market Signals
Indicator
BGSF
CYPH
Relative Strength Index (RSI) 50.20 50.79
Support Level $5.49 $0.58
Resistance Level $5.79 $0.80
Average True Range (ATR) 0.15 0.07
MACD -0.02 0.02
Stochastic Oscillator 18.18 82.64

Price Performance

Historical Comparison
BGSF
CYPH

About BGSF BGSF Inc.

BGSF Inc is a national provider of consulting, managed services, and professional workforce solutions. The company operates in one segment of Property Management, which includes centralized support services through executive, marketing, human resources, information technology, accounting, treasury, and billing operations.

About CYPH Cypherpunk Technologies Inc.

Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.

Share on Social Networks: